Kezdőlap・Részvénylista・Pfizer

Pfizer

Nyitva

SzektorEgészségügy

25.36 1.2

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

24.71

Maximum

25.63

Fő mutatók
By Trading Economics
Bevétel	4.3B 2.7B
Értékesítés	-3.1B 14B
P/E Szektor átlag	18.832 64.641
Egy részvényre jutó nyereség	0.75
Osztalékhozam	7.01
Profit margin	18.656
Munkavállalók	75,000
EBITDA	4.3B 5B

Ajánlások
By TipRanks
Ajánlások	Semleges
12 hónapos előrejelzés	+13.95% upside

Osztalékok
By Acuity
Osztalékhozam Szektor átlag	7.01% 2.31%
Következő eredményjelentés	2026. aug. 4.
Következő osztalékfizetési dátum	2026. szept. 1.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-9.7B 140B
Előző nyitás	24.16
Előző zárás	25.36

Hangulat hírek alapján

By Acuity

32%

68%

100 / 340 Rangsor szerint Healthcare

Pfizer Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 3. 23:46 UTC

Social Media

Pfizer Inc shares are higher in after-market trading ahead of earnings. The stock remains above its 20-day moving average, reflecting positive market sentiment.

2026. júl. 31. 23:06 UTC

Pfizer Inc shares are higher in after-market hours, reflecting slight gains since Friday's close. The stock remains near the upper end of its one-month range.

2026. júl. 30. 23:26 UTC

Event

Pfizer shares are higher in after-market trading following Phase 3 trial results for LITFULO in nonsegmental vitiligo, despite three prior sessions of lower closes.

2026. júl. 29. 23:16 UTC

News

Pfizer and BioNTech received European Commission approval for their XFG-adapted COVID-19 vaccine, valid across all EU member states. Shares are trading roughly flat after-market.

2026. júl. 28. 23:26 UTC

Pfizer Inc shares are lower in after-market hours, reversing an earlier gain. The stock remains above its 20-day moving average.

2026. júl. 27. 18:56 UTC

Pfizer Inc is trading higher, driven by gains in the Pharmaceuticals sub-sector. Shares pulled back earlier in the session from a session high.

2026. júl. 24. 18:06 UTC

Pfizer Inc. shares are lower today, reflecting broader market trends. Earlier, shares fell significantly before partially recovering amid declining crude oil prices.

2026. júl. 23. 09:41 UTC

News

Pfizer Inc. shares are higher in pre-market trading following FDA acceptance of a Priority Review for TALZENNA in combination with XTANDI for prostate cancer.

2026. júl. 22. 23:02 UTC

News

Pfizer Inc. shares are higher in after-market hours following the FDA's acceptance of a Priority Review for TALZENNA and XTANDI in prostate cancer treatment.

2026. júl. 21. 23:11 UTC

News

Pfizer Inc. options trading showed light volume, with calls outpacing puts and a put/call ratio of 0.56. Shares were little changed in after-market hours.

2026. júl. 20. 23:16 UTC

Pfizer Inc shares are higher in after-market trading, maintaining above their 20-day moving average despite broader market pressures from rising treasury yields.

Társak összehasonlítása

Árváltozás

Pfizer Előrejelzés

Célár

By TipRanks

13.95% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 28.5 USD 13.95%

Magas 35 USD

Alacsony 25 USD

22 Wall Street elemző 12 hónapos célárain alapulva a(z)Pfizer termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

22 ratings

Vétel

Tartás

Eladás

22 Wall Street elemző célárain alapulva a(z)Pfizer termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

100 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.